Cost of initial therapy in the electrophysiological study versus ECG monitoring trial (ESVEM)

N. A. Omoigui, F. I. Marcus, J. W. Mason, E. A. Hahn, V. L. Hartz, M. A. Hlatky

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: patients randomized to either serial electrophysiological testing (EPS) or serial Holter monitoring (HM) to guide antiarrhythmic therapy for life-threatening ventricular arrhythmias had equivalent rates of mortality and arrhythmia recurrence in the ESVEM study. This report analyzes the effects of EPS, HM, and clinical factors on the charges for initial evaluation and management of patients with life-threatening ventricular arrhythmias. Methods and Results: Ten of 14 clinical centers participating in ESVEM provided bills from the initial hospitalization for randomized patients. Predictors of charges (1991 dollars) were analyzed by linear regression after logarithmic transformation. Initial hospital charge data were obtained for 286 patients randomized in ESVEM (88% of patients eligible for this substudy, 59% of all ESVEM patients). Patients with charge data were somewhat more likely to be older, to be female, and to have failed previous antiarrhythmic drug therapy at study entry and were less likely to have a drug predicted effective after randomization. Mean overall hospital charges were $35 986 (SD, $32 628) with a median of $24 532 (interquartile range, $16 126 to $43 593). Prerandomization patient characteristics generally had insignificant effects on charges, with the exception of presentation with resuscitated sudden death (28% increase in charges, P=.01) and heart failure (26% increase in charges, P=.02). Patients randomized to EPS had higher mean charges for evaluation ($42 002 versus $29 970, P=.0015) as well as more drug trials (3.0 versus 2.1, P=.0001) and a longer hospital stay (19.6 versus 13.9 days, P=.0007). In a multivariate regression model, failure to find an effective drug (P=.0001), the number of drug trials (P=.0001), and resuscitated sudden death as the presenting arrhythmia (P=.0001) were the only independent predictors of higher initial charges. Conclusions: (1) Initial hospital charges are significantly higher for EPS-guided than HM- guided therapy. (2) The higher charges for EPS-guided therapy were due to a greater number of drug trials and a lower probability of finding an effective drug. (3) Failure to find an effective drug, a larger number of drag trials, and a history of resuscitated sudden death independently predict higher charges.

Original languageEnglish (US)
Pages (from-to)1070-1076
Number of pages7
JournalCirculation
Volume91
Issue number4
DOIs
StatePublished - Feb 15 1995

Fingerprint

Electrocardiography
Costs and Cost Analysis
Hospital Charges
Ambulatory Electrocardiography
Cardiac Arrhythmias
Pharmaceutical Preparations
Sudden Death
Therapeutics
Anti-Arrhythmia Agents
Physiologic Monitoring
Random Allocation
Linear Models
Length of Stay
Hospitalization
Heart Failure
Recurrence
Drug Therapy
Mortality

Keywords

  • clinical trials
  • death, sudden
  • electrophysiology

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Omoigui, N. A., Marcus, F. I., Mason, J. W., Hahn, E. A., Hartz, V. L., & Hlatky, M. A. (1995). Cost of initial therapy in the electrophysiological study versus ECG monitoring trial (ESVEM). Circulation, 91(4), 1070-1076. https://doi.org/10.1161/01.CIR.91.4.1070
Omoigui, N. A. ; Marcus, F. I. ; Mason, J. W. ; Hahn, E. A. ; Hartz, V. L. ; Hlatky, M. A. / Cost of initial therapy in the electrophysiological study versus ECG monitoring trial (ESVEM). In: Circulation. 1995 ; Vol. 91, No. 4. pp. 1070-1076.
@article{7f6c8a3d506649838f4e079c78d1faa3,
title = "Cost of initial therapy in the electrophysiological study versus ECG monitoring trial (ESVEM)",
abstract = "Background: patients randomized to either serial electrophysiological testing (EPS) or serial Holter monitoring (HM) to guide antiarrhythmic therapy for life-threatening ventricular arrhythmias had equivalent rates of mortality and arrhythmia recurrence in the ESVEM study. This report analyzes the effects of EPS, HM, and clinical factors on the charges for initial evaluation and management of patients with life-threatening ventricular arrhythmias. Methods and Results: Ten of 14 clinical centers participating in ESVEM provided bills from the initial hospitalization for randomized patients. Predictors of charges (1991 dollars) were analyzed by linear regression after logarithmic transformation. Initial hospital charge data were obtained for 286 patients randomized in ESVEM (88{\%} of patients eligible for this substudy, 59{\%} of all ESVEM patients). Patients with charge data were somewhat more likely to be older, to be female, and to have failed previous antiarrhythmic drug therapy at study entry and were less likely to have a drug predicted effective after randomization. Mean overall hospital charges were $35 986 (SD, $32 628) with a median of $24 532 (interquartile range, $16 126 to $43 593). Prerandomization patient characteristics generally had insignificant effects on charges, with the exception of presentation with resuscitated sudden death (28{\%} increase in charges, P=.01) and heart failure (26{\%} increase in charges, P=.02). Patients randomized to EPS had higher mean charges for evaluation ($42 002 versus $29 970, P=.0015) as well as more drug trials (3.0 versus 2.1, P=.0001) and a longer hospital stay (19.6 versus 13.9 days, P=.0007). In a multivariate regression model, failure to find an effective drug (P=.0001), the number of drug trials (P=.0001), and resuscitated sudden death as the presenting arrhythmia (P=.0001) were the only independent predictors of higher initial charges. Conclusions: (1) Initial hospital charges are significantly higher for EPS-guided than HM- guided therapy. (2) The higher charges for EPS-guided therapy were due to a greater number of drug trials and a lower probability of finding an effective drug. (3) Failure to find an effective drug, a larger number of drag trials, and a history of resuscitated sudden death independently predict higher charges.",
keywords = "clinical trials, death, sudden, electrophysiology",
author = "Omoigui, {N. A.} and Marcus, {F. I.} and Mason, {J. W.} and Hahn, {E. A.} and Hartz, {V. L.} and Hlatky, {M. A.}",
year = "1995",
month = "2",
day = "15",
doi = "10.1161/01.CIR.91.4.1070",
language = "English (US)",
volume = "91",
pages = "1070--1076",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

Cost of initial therapy in the electrophysiological study versus ECG monitoring trial (ESVEM). / Omoigui, N. A.; Marcus, F. I.; Mason, J. W.; Hahn, E. A.; Hartz, V. L.; Hlatky, M. A.

In: Circulation, Vol. 91, No. 4, 15.02.1995, p. 1070-1076.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cost of initial therapy in the electrophysiological study versus ECG monitoring trial (ESVEM)

AU - Omoigui, N. A.

AU - Marcus, F. I.

AU - Mason, J. W.

AU - Hahn, E. A.

AU - Hartz, V. L.

AU - Hlatky, M. A.

PY - 1995/2/15

Y1 - 1995/2/15

N2 - Background: patients randomized to either serial electrophysiological testing (EPS) or serial Holter monitoring (HM) to guide antiarrhythmic therapy for life-threatening ventricular arrhythmias had equivalent rates of mortality and arrhythmia recurrence in the ESVEM study. This report analyzes the effects of EPS, HM, and clinical factors on the charges for initial evaluation and management of patients with life-threatening ventricular arrhythmias. Methods and Results: Ten of 14 clinical centers participating in ESVEM provided bills from the initial hospitalization for randomized patients. Predictors of charges (1991 dollars) were analyzed by linear regression after logarithmic transformation. Initial hospital charge data were obtained for 286 patients randomized in ESVEM (88% of patients eligible for this substudy, 59% of all ESVEM patients). Patients with charge data were somewhat more likely to be older, to be female, and to have failed previous antiarrhythmic drug therapy at study entry and were less likely to have a drug predicted effective after randomization. Mean overall hospital charges were $35 986 (SD, $32 628) with a median of $24 532 (interquartile range, $16 126 to $43 593). Prerandomization patient characteristics generally had insignificant effects on charges, with the exception of presentation with resuscitated sudden death (28% increase in charges, P=.01) and heart failure (26% increase in charges, P=.02). Patients randomized to EPS had higher mean charges for evaluation ($42 002 versus $29 970, P=.0015) as well as more drug trials (3.0 versus 2.1, P=.0001) and a longer hospital stay (19.6 versus 13.9 days, P=.0007). In a multivariate regression model, failure to find an effective drug (P=.0001), the number of drug trials (P=.0001), and resuscitated sudden death as the presenting arrhythmia (P=.0001) were the only independent predictors of higher initial charges. Conclusions: (1) Initial hospital charges are significantly higher for EPS-guided than HM- guided therapy. (2) The higher charges for EPS-guided therapy were due to a greater number of drug trials and a lower probability of finding an effective drug. (3) Failure to find an effective drug, a larger number of drag trials, and a history of resuscitated sudden death independently predict higher charges.

AB - Background: patients randomized to either serial electrophysiological testing (EPS) or serial Holter monitoring (HM) to guide antiarrhythmic therapy for life-threatening ventricular arrhythmias had equivalent rates of mortality and arrhythmia recurrence in the ESVEM study. This report analyzes the effects of EPS, HM, and clinical factors on the charges for initial evaluation and management of patients with life-threatening ventricular arrhythmias. Methods and Results: Ten of 14 clinical centers participating in ESVEM provided bills from the initial hospitalization for randomized patients. Predictors of charges (1991 dollars) were analyzed by linear regression after logarithmic transformation. Initial hospital charge data were obtained for 286 patients randomized in ESVEM (88% of patients eligible for this substudy, 59% of all ESVEM patients). Patients with charge data were somewhat more likely to be older, to be female, and to have failed previous antiarrhythmic drug therapy at study entry and were less likely to have a drug predicted effective after randomization. Mean overall hospital charges were $35 986 (SD, $32 628) with a median of $24 532 (interquartile range, $16 126 to $43 593). Prerandomization patient characteristics generally had insignificant effects on charges, with the exception of presentation with resuscitated sudden death (28% increase in charges, P=.01) and heart failure (26% increase in charges, P=.02). Patients randomized to EPS had higher mean charges for evaluation ($42 002 versus $29 970, P=.0015) as well as more drug trials (3.0 versus 2.1, P=.0001) and a longer hospital stay (19.6 versus 13.9 days, P=.0007). In a multivariate regression model, failure to find an effective drug (P=.0001), the number of drug trials (P=.0001), and resuscitated sudden death as the presenting arrhythmia (P=.0001) were the only independent predictors of higher initial charges. Conclusions: (1) Initial hospital charges are significantly higher for EPS-guided than HM- guided therapy. (2) The higher charges for EPS-guided therapy were due to a greater number of drug trials and a lower probability of finding an effective drug. (3) Failure to find an effective drug, a larger number of drag trials, and a history of resuscitated sudden death independently predict higher charges.

KW - clinical trials

KW - death, sudden

KW - electrophysiology

UR - http://www.scopus.com/inward/record.url?scp=0028957383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028957383&partnerID=8YFLogxK

U2 - 10.1161/01.CIR.91.4.1070

DO - 10.1161/01.CIR.91.4.1070

M3 - Article

C2 - 7850943

AN - SCOPUS:0028957383

VL - 91

SP - 1070

EP - 1076

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 4

ER -